An 8-month-old male with X-linked lymphoproliferative disease underwent an unrelated, partially matched (with major mismatch at DR locus), cord blood stem cell transplant. Four months following the transplant, he developed immune thrombocytopenia with hemolytic anemia (Evans syndrome). He received multiple courses of intravenous immunoglobulin, anti-Rh D immunoglobulin, a pulse of high-dose corticosteroids and cyclosporine with some improvement of hemolytic anemia, but no improvement of the thrombocytopenia. Addition of vincristine, resulted in long-term resolution of thrombocytopenia and anemia. No major toxicity was observed during treatment. Vincristine should be considered as a treatment for refractory immune thrombocytopenia after hematopoietic stem cell transplantation.
Immune thrombocytopenic purpura (ITP) is a disorder characterized by autoimmune platelet destruction. The illness is mediated by IgG autoantibodies which bind to the platelet membrane leading to platelet destruction by the reticuloendothelial system. 1 Thrombocytopenia may be associated with graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT) and is an indicator of poor prognosis. 2 Autoimmune thrombocytopenia following BMT, but independent of GVHD, has been observed rarely. It often requires therapy with intravenous immunoglobulin (IVIG), anti-D immunoglobulin, 3 increased immunosuppression, splenectomy or androgens. Recently, hemolytic anemia, as a primary manifestation of de novo chronic GVHD has been reported. 4 This report describes the course of a 12-month-old boy who developed ITP along with hemolytic anemia 4 months after unrelated cord blood transplant.
Case report
BL, an 8-month-old male with X-linked lymphoproliferative disease (XLPD) underwent a hematopoietic stem cell trsansplant using an unrelated cord blood from the New York Cord Blood Repository. The donor and recipient were matched at the A, B and one DR loci; there was a single major mismatch at the remaining DR locus.
The patient was conditioned with busulfan (16 mg/kg orally in 16 divided doses over 4 days), cyclophosphamide (15 mg/kg/day intravenously for 4 days) and etoposide (10 mg/kg/day intravenously for 3 days). Mesna uroprophylaxis was used, as well as anti-thymocyte globulin (ATG) (15 mg/kg intravenously for six doses). Prophylaxis against graft-versus-host disease used cyclosporine (CYA) and solumedrol. Granulocyte colony-stimulating factor was used after transplant until the absolute neutrophil count (ANC) exceeded 10 9 /l. The patient engrafted promptly. His ANC exceeded 1.5 × 10 9 /l for 3 days by day 25. There was evidence of trilineage engraftment by day 53. He experienced a maximum GVHD of grade II skin and grade I liver.
Four months after transplant, the patient developed severe thrombocytopenia (platelet count less than 10 Treatment with increased doses of CYA, pulse of the high-dose corticosteroids (30 mg/kg/day for 3 days), infusion of paternal plasma and IVIG was unsuccessful. The addition of anti-Rh D immunoglobulin (Rho Gam) failed to increase the platelet count above 10 10 /l. Repeat bone marrow aspirate showed 70% cellularity with trilineage maturation; donor hematopoiesis was documented by analysis of restriction fragment length polymorphisms. Study of indium-labeled platelet survival did not show the spleen to be a major site of platelet destruction.
Vincristine (VCR) (1.5 mg/m 2 /week) by intravenous infusion over 4 h was added to the treatment with CYA, corticosteroids and IVIG. Within 5 weeks, the patient's platelet count as well as anemia and neutropenia, stabilized and subsequently improved (Figure 1 ). He received a total of seven doses of VCR. VCR doses were gradually spread out and eventually discontinued, without recurrence of thrombocytopenia and minimal evidence of neurotoxicity (foot drop). The patient continues to thrive with continued evidence of trilineage hematopoiesis and gradual immunologic reconstitution.
Discussion
Chronic GVHD occurs in over 50% of long-term survivors of BMT. Usually symptoms develop immediately following acute GVHD, or after a quiescent period. About 20% of patients develop de novo chronic GVHD. Immunemediated cytopenia has been described in patients after allogeneic and autologous bone marrow transplant. 5 Autoimmune thrombocytopenia as a manifestation of GVHD has been described previously. 2 Autoimmune hemolytic anemia has been described in a patient who underwent T cell-depleted allogeneic bone marrow transplant. 6 Evans syndrome was described in children who underwent BMT from matched unrelated donors, 7 as well as in adult patients following partially mismatched donor BMT, 4 or autologous BMT. 8 It has been noticed that many patients who developed Evans syndrome following BMT received potent T cell suppression with ATG and/or OKT3 as part of the conditioning regimen. 8 Severe T cell suppression can lead to B cell dysregulation with subsequent autoimmune effects. Our patient received ATG as a part of his pre-transplant conditioning. Thrombocytopenia and Coombs' positive hemolytic anemia (Evans syndrome) developed in our patient 4 months after unrelated cord blood transplantation. Although many cases of Evans syndrome also have autoimmune neutropenia, our patient had a negative anti-neutrophil antibody titer. Initial pancytopenia was very likely the result of both destruction and poor production of cells by recovering bone marrow.
The usual treatment of acute ITP includes IVIG, anti-D immunoglobulin or steroids. 9 Less frequently, thrombocytopenia is refractory to these treatments and additional treatment is required. In our patient, it appears that CYA, IVIG, anti-D immunoglobulin and steroids (as well as high-dose steroids) had some beneficial effect on the hemolytic anemia, but did not improve the platelet count. Since the indium-labeled platelet survival study did not identify the spleen as a major site of platelet destruction, we did not consider splenectomy in this already immunocompromised patient. There are many treatments reported to be successful in patients with refractory ITP. These include the use of danazol, colchicine, ascorbate, plasmapheresis with immunoadsorption, azathioprine, vinca alkaloids, combination chemotherapy, splenic irradiation and interferon-␣ (summarized in Ref. 1). Due to the patient's age and his clinical condition, we chose to use VCR at this stage of his disease.
Experience with use of VCR as a therapy for destructive thrombocytopenia is limited. The efficacy of VCR in treatment of immune thrombocytopenia has been reported. 10 VCR has been shown to increase the platelet count in patients with thrombotic thrombocytopenic purpura (TTP) 11 and with paroxysmal nocturnal hemoglobinuria. 12 Limited experience with the use of VCR for ITP does not allow precise assessment of its efficacy. Documented toxic effects of VCR remain the reason why this drug is not considered as a primary therapy for ITP. The advantage of VCR is its fast action. 13 VCR binds to tubulin, the structural protein in platelet membranes. Immunoglobulin-coated platelets are removed by macrophages which get destroyed during that process. In addition, it has been observed that vinca alkaloids can produce thrombocytosis in patients, 14 presumably due to enhanced thrombocytopoiesis. 15 VCR suppresses cellular and humoral immunity. 16 When VCR is given as an intravenous bolus, it is rapidly cleared from plasma. 17 Since platelets in patients with ITP have a rapid turnover, it has been postulated that a slow infusion of VCR might make the drug interact with several generations of platelets. 18 Two studies which used slow infusion of vinca alkaloids, 19 or slow infusion of VCR only, 20 showed evidence that this method of administration is preferable for the treatment of ITP. Thus, we decided to use VCR given by slow infusion over 4 h. VCR was chosen over vinblastin because the latter is associated with myelosuppression. Toxic sideeffects of VCR, especially neurotoxicity, are the main reason why prolonged chronic administration should be avoided. 21 In previous studies, 19, 20, 22 a maximum of 6 weekly doses were used. Our patient did not show any signs of neurotoxicity until after the last dose, when he developed foot drop, which spontaneously resolved after discontinuation of VCR.
In summary, we report refractory autoimmune throm-bocytopenic purpura which presented as Evans syndrome, after partially matched unrelated cord blood transplantation. Despite increased use of cord blood as a source of stem cells, this complication following cord blood tranplant has not been reported to our knowledge. Whether this was an isolated manifestation of chronic GVHD remains unclear. Our patient's condition improved after slow infusion of VCR; this approach should be considered as a treatment of refractory autoimmune thrombocytopenia after hematopoietic stem cell transplantation.
